15 Costly Drugs Will Get Medicare Price Cuts in 2027: Will You Save?
The Centers for Medicare & Medicaid Services extended a safety net to older Americans by announcing significant price reductions on 15 high-cost prescription drugs, effective in 2027.
On November 25, 2025, the Centers for Medicare & Medicaid Services (CMS) announced significant price reductions for 15 high-cost prescription drugs used by millions of Medicare beneficiaries. That's a major win for older Americans.
The negotiated "maximum fair prices," made possible by the 2022 Inflation Reduction Act, promise to save the program $12 billion annually compared with last year's Medicare spending on 15 widely used drugs to treat cancer and other serious chronic conditions that hit older adults hardest.
Previously, the Biden administration reached deals to lower the costs of 10 prescription drugs, including several for heart disease and diabetes, which are set to take effect in 2026. This latest round of price negotiations will go into effect in 2027, with seniors expected to see an estimated $685 million in out-of-pocket relief.
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Historically, prescription drug costs have wreaked havoc on many seniors' budgets, with some rationing doses or skipping their meds altogether due to high costs, according to a survey by research group KFF.
For the roughly 5.3 million Medicare beneficiaries who take these 15 medications, and the new $2,100 annual out-of-pocket cap in Medicare Part D, starting in 2026, 2027 can’t come soon enough.
For decades, Medicare was prohibited by law from negotiating drug prices directly with manufacturers, resulting in older Americans paying two to four times what patients in Europe or Canada paid for the same medicines.
Seniors like 72-year-old retiree Ryan Whitworth of Florida, who relies on Xtandl for prostate cancer, could see his monthly copays halved. “Finally, I won’t have to choose between meds and groceries,” he told Kiplinger.
Below is the full list of the 15 drugs and their new Medicare maximum fair prices compared with the 2024 list prices. All figures are for a typical 30-day supply. The numbers are rounded to the nearest dollar where applicable.
Drug Name | Commonly Treated Conditions | 2024 List Price | 2027 Medicare Price | % Reduction |
Ozempic; Rybelsus; Wegovy | Type 2 diabetes; Type 2 diabetes & cardiovascular disease; Cardiovascular disease & obesity/overweight | $959 | $274 | -71% |
Trelegy Ellipta | Asthma; Chronic obstructive pulmonary disease | $654 | $175 | -73% |
Xtandi | Prostate cancer | $13,480 | $7,004 | -48% |
Pomalyst | Kaposi sarcoma; Multiple myeloma | $21,744 | $8,650 | -60% |
Ofev | Idiopathic pulmonary fibrosis | $12,622 | $6,350 | -50% |
Ibrance | Breast cancer | $15,741 | $7,871 | -50% |
Linzess | Chronic idiopathic constipation; irritable bowel syndrome with constipation | $539 | $136 | -75% |
Calquence | Chronic lymphocytic leukemia/small lymphocytic lymphoma; Mantle cell lymphoma | $14,228 | $8,600 | -40% |
Austedo; Austedo XR | Chorea in Huntington’s disease; Tardive dyskinesia | $6,623 | $4,093 | -38% |
Breo Ellipta | Asthma; Chronic obstructive pulmonary disease | $397 | $67 | -83% |
Xifaxan | Hepatic encephalopathy; Irritable bowel syndrome with diarrhea | $2,696 | $1,000 | -63% |
Vraylar | Bipolar 1 disorder; Major depressive disorder; Schizophrenia | $1,376 | $770 | -44% |
Tradjenta | Type 2 diabetes | $488 | $78 | -84% |
Janumet; Janumet XR | Type 2 diabetes | $526 | $80 | -85% |
Otezla; Otezla XR | Oral ulcers in Behçet’s Disease; Plaque psoriasis; Psoriatic arthritis | $4,722 | $1,650 | -65% |
The “2024 List Price” column shows the gross Wholesale Acquisition Cost (WAC) that Medicare Part D plans were charged in 2024 for a 30-day supply, before any rebates or discounts.
The “2027 Medicare Price” column is the Maximum Fair Price (MFP) manufacturers must offer Medicare starting January 1, 2027, for a 30-day supply.
Sources: CMS, November 2025 (pdf); Medicare prescription drug affordability fact sheet; Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability, Year 2027 (pdf)
List prices reflect typical Part D gross costs before rebates.
Related content
- 16 Strategies to Save Money on Prescription Drugs
- Here Are the 10 Medicare Negotiated Drug Prices
- Medicare to Cover Obesity Drugs Under Trump Deal for as Little as $50. What You Need to Know
- Seven Medicare Changes Coming in 2026
- Brace for Higher Health Costs in 2026: A Look at Projected Medicare Premiums
-
How Charitable Trusts Benefit You and Your Favorite CharitiesThese dual-purpose tools let affluent families combine philanthropic goals with advanced tax planning to generate income, reduce estate taxes and preserve wealth.
-
A 5-Step Plan for Parents of Children With Special NeedsGuidance to help ensure your child's needs are supported now and in the future – while protecting your own financial well-being.
-
How Financial Advisers Can Best Help Widowed and Divorced WomenApproaching conversations with empathy and compassion is key to helping them find clarity and confidence and take control of their financial futures.
-
A 5-Step Plan for Parents of Children With Special Needs, From a Financial Planner
Guidance to help ensure your child's needs are supported now and in the future – while protecting your own financial well-being.
-
I'm 59 With $1.7 Million Saved and Just Lost My Job. Should I Retire at 59½, or Find New Work?We asked professional wealth planners for advice.
-
A Wealth Adviser Explains: 4 Times I'd Give the Green Light for a Roth Conversion (and 4 Times I'd Say It's a No-Go)Roth conversions should never be done on a whim — they're a product of careful timing and long-term tax considerations. So how can you tell whether to go ahead?
-
A 4-Step Anxiety-Reducing Retirement Road Map, From a Financial AdviserThis helpful process covers everything from assessing your current finances and risks to implementing and managing your personalized retirement income plan.
-
I Drive and Collect Classic Cars: Here’s How I Got in the Game Without Spending a FortuneAre classic cars a hobby or an investment strategy — or both? Either way, the vintage car scene is much cooler and more affordable than you think.
-
The $183,000 RMD Shock: Why Roth Conversions in Your 70s Can Be RiskyConverting retirement funds to a Roth is a smart strategy for many, but the older you are, the less time you have to recover the tax bite from the conversion.
-
A Financial Pro Breaks Retirement Planning Into 5 Manageable PiecesThis retirement plan focuses on five key areas — income generation, tax management, asset withdrawals, planning for big expenses and health care, and legacy.
-
4 Financial To-Dos to Finish 2025 Strong and Start 2026 on Solid GroundDon't overlook these important year-end check-ins. Missed opportunities and avoidable mistakes could end up costing you if you're not paying attention.
